Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy
| Autor: | A. Sarah Walker, Osamah Hamouda, Virginie Rondeau, Maria Dorrucci, Heiner C. Bucher, Maria Prins, Geneviève Chêne, Kholoud Porter, Caroline A. Sabin, Rodolphe Thiébaut, Benoît Marin, Dominique Costagliola |
|---|---|
| Přispěvatelé: | Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Basel Institute for Clinical Epidemiology, University Hospital Basel [Basel], Epidémiologie Clinique et Traitement de l'Infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento di Malattie Infettive, Reparto di Epidemiologia, Istituto Superiore di Sanita [Rome], Department of Infectious Disease Epidemiology, Robert Koch Institute [Berlin] (RKI), Cluster Infectious Diseases, Amsterdam BioMed Cluster, Medical Research Council Clinical Trials Unit (MRC CTU), University College of London [London] (UCL), Research Department of Infection and Population Health [London], CASCADE has been funded through grants from the European Union BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708 and LSHP-CT-2006-018949., Istituto Superiore di Sanità (ISS), AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Infectious diseases |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Male
MESH: CD4 Lymphocyte Count medicine.medical_treatment CD4 cell count Disease MESH: Epidemiologic Methods MESH: Antiretroviral Therapy Highly Active Hepatitis Liver disease 0302 clinical medicine Antiretroviral Therapy Highly Active Neoplasms Immunology and Allergy MESH: Neoplasms 030212 general & internal medicine Causes of death Immunodeficiency MESH: Aged 0303 health sciences MESH: Middle Aged MESH: AIDS-Related Opportunistic Infections Liver Diseases Immunosuppression Middle Aged Human Immunodeficiency Virus/AIDS Antiretroviral therapy 3. Good health Infectious Diseases Cardiovascular Diseases MESH: Young Adult Female Viral disease Adult medicine.medical_specialty MESH: Immune Tolerance MESH: Liver Diseases Adolescent Immunology Article Young Adult 03 medical and health sciences Acquired immunodeficiency syndrome (AIDS) Internal medicine Immune Tolerance medicine Humans Seroconversion highly active Aged MESH: Acquired Immunodeficiency Syndrome MESH: Adolescent Acquired Immunodeficiency Syndrome MESH: Humans AIDS-Related Opportunistic Infections 030306 microbiology business.industry MESH: Cardiovascular Diseases MESH: Adult medicine.disease MESH: Male CD4 Lymphocyte Count Neoplasm [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Bacterial infection Epidemiologic Methods business MESH: Female |
| Zdroj: | AIDS AIDS, Lippincott, Williams & Wilkins, 2009, 23 (13), pp.1743-53. ⟨10.1097/QAD.0b013e32832e9b78⟩ AIDS. Official journal of the international AIDS Society AIDS. Official journal of the international AIDS Society, 2009, 23 (13), pp.1743-53. ⟨10.1097/QAD.0b013e32832e9b78⟩ AIDS (London, England), 23(13), 1743-1753. Lippincott Williams and Wilkins |
| ISSN: | 0269-9370 1473-5571 |
| DOI: | 10.1097/qad.0b013e32832e9b78 |
| Popis: | International audience; OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). DESIGN: Observational multicentre cohorts. METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification. RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|